logo
Sign in

TAK Stock Price, Chart, Stats & News

Takeda Pharmaceutical Company Limited
Save
49.29B
Market cap
42.16x
Current P/E
9.62x
Forward P/E
3.98%
Dividend yield

TAK chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
62.11%
Operating margin
8.31%
Pretax margin
4.63%
Net margin
2.56%
Effective tax rate
44.63%
ROA
0.74%
ROE
1.61%
D/E
0.64x
Interest coverage ratio
1.18x

TAK valuation

P/E
42.16x
P/S
2.02x
P/B
1.19x
P/CF
7.71x
P/FCF
9.48x
P/OCF
7.71x
PEG
0.00x
EV multiple
3.49x

About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands.

Similar securities

Based on sector and market capitalization

Report issue